Loading
Whether a drug gets into the brain is measured early in development but rarely published. Making that number public would show which existing drugs could treat brain disease.
Unbound brain-to-plasma partition coefficients are routinely generated in preclinical development and almost never disclosed, so clinicians and academic groups cannot tell which approved drugs are worth testing in central nervous system disease. A disclosure requirement at investigational new drug or marketing authorisation stage, or a voluntary public registry, would create a searchable resource at near-zero cost.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, ClinicalTrials.gov.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Failures are hidden.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Knowledge reaches practice too slowly.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Knowledge reaches practice too slowly.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Knowledge reaches practice too slowly.
Shares FDA Oncology Approvals (OCE) & Novel Drug Approvals, Failures are hidden, Knowledge reaches practice too slowly.
Shares DrugBank & ChEMBL, FDA Oncology Approvals (OCE) & Novel Drug Approvals.
Shares DrugBank & ChEMBL, Failures are hidden.